{"id":"oxybutynin-transdermal-patch","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Dry mouth"},{"rate":"5-15","effect":"Application site erythema or pruritus"},{"rate":"5-10","effect":"Constipation"},{"rate":"5-10","effect":"Blurred vision"},{"rate":"3-8","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1231","moleculeType":"Small molecule","molecularWeight":"357.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxybutynin antagonizes M3 muscarinic receptors on detrusor muscle, which suppresses the parasympathetic-mediated contractions responsible for urinary urgency and incontinence. The transdermal patch formulation provides sustained drug delivery over several days, improving tolerability compared to oral administration by reducing peak plasma concentrations and associated anticholinergic side effects.","oneSentence":"Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:07.362Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"},{"name":"Neurogenic detrusor overactivity in spinal cord injury patients"}]},"trialDetails":[{"nctId":"NCT03952299","phase":"PHASE3","title":"Oxybutynin for Post-surgical Bladder Pain and Urgency","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2021-09-01","conditions":"Overactive Bladder Syndrome, Neuropathic Bladder","enrollment":100},{"nctId":"NCT07081906","phase":"NA","title":"Transdermal Versus Oral Oxybutynin in Pediatric OAB","status":"COMPLETED","sponsor":"Dr. Lutfi Kirdar Kartal Training and Research Hospital","startDate":"2019-02-15","conditions":"Overactive Bladder (OAB), Drug Delivery Systems, Anticholinergic Side Effects","enrollment":90},{"nctId":"NCT03205605","phase":"EARLY_PHASE1","title":"Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-01-02","conditions":"Heat Effect","enrollment":13},{"nctId":"NCT04534491","phase":"PHASE3","title":"Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05-25","conditions":"Overactive Bladder","enrollment":855},{"nctId":"NCT00224016","phase":"PHASE4","title":"Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2004-12","conditions":"Detrusor Hyperreflexia","enrollment":57},{"nctId":"NCT00224029","phase":"PHASE4","title":"A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2004-12","conditions":"Detrusor Hyperreflexia","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"CONDITION AGGRAVATED"},{"count":2,"reaction":"MUSCULAR WEAKNESS"},{"count":2,"reaction":"PAIN"},{"count":1,"reaction":"ANGIONEUROTIC OEDEMA"},{"count":1,"reaction":"AORTIC STENOSIS"},{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"BREAST CANCER METASTATIC"},{"count":1,"reaction":"CARDIAC FAILURE"},{"count":1,"reaction":"CHEST PAIN"},{"count":1,"reaction":"CORONARY ARTERY DISEASE"}],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ditropan XL"],"phase":"phase_3","status":"active","brandName":"Oxybutynin Transdermal Patch","genericName":"Oxybutynin Transdermal Patch","companyName":"University of California, Davis","companyId":"university-of-california-davis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency, Neurogenic detrusor overactivity in spinal cord injury patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}